Histidine ( DrugBank: Histidine )


3 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2
169Menkes disease4
170Occipital horn syndrome1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04764383
(ClinicalTrials.gov)
January 1, 202218/2/2021Histaminergic Basis of Fatigue in Multiple SclerosisHistaminergic Basis of Fatigue in Multiple SclerosisMultiple SclerosisDrug: L-Histidine;Drug: Placebo;Drug: LodosynUniversity of MiamiNULLWithdrawn18 Years60 YearsAll0Phase 2United States
2NCT03266965
(ClinicalTrials.gov)
March 23, 20184/7/2017Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachHistaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachMultiple SclerosisDrug: Carbidopa;Dietary Supplement: L-HistidineUniversity of MiamiUnited States Department of DefenseCompleted18 Years60 YearsAll18Phase 1United States

169. Menkes disease


Clinical trials : 7 Drugs : 7 - (DrugBank : 4) / Drug target genes : 9 - Drug target pathways : 14
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000030626
2014/11/2828/12/2017Investigation on the effectiveness of histidine copper treatment of Menkes disease patients Menkes diseaseWeekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period.Hamamatsu University School of MedicineNULLComplete: follow-up completeNot applicableNot applicableMale and Female2Not selectedJapan
2JPRN-UMIN000005259
2011/03/0318/03/2011Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease Menkes diseasegive a dose of copper-histidine and diethyldithiocarbamateKobe Unniversitu Graduate School of MedicineNULLComplete: follow-up completeNot applicableNot applicableMale and Female2Not selectedJapan
3NCT00811785
(ClinicalTrials.gov)
February 27, 200918/12/2008Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMolecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMenkes Disease;Occipital Horn Syndrome;Unexplained Copper DeficiencyDrug: Copper HistidineCyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)CompletedN/A80 YearsAll93Phase 3United States
4NCT00001262
(ClinicalTrials.gov)
June 19903/11/1999Copper Histidine Therapy for Menkes DiseasesEarly Copper Histidine Therapy in Menkes DiseaseKinky Hair SyndromeDrug: Copper HistidineEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompletedN/AN/AAll60Phase 1/Phase 2United States

170. Occipital horn syndrome


Clinical trials : 2 Drugs : 4 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 14
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00811785
(ClinicalTrials.gov)
February 27, 200918/12/2008Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMolecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMenkes Disease;Occipital Horn Syndrome;Unexplained Copper DeficiencyDrug: Copper HistidineCyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)CompletedN/A80 YearsAll93Phase 3United States